Drugs & Targets FDA approves Rybrevant Faspro as dual-targeted therapy for advanced head and neck cancer November 06, 2026Vol.52 No.41
Drugs & Targets FDA grants priority review to Brukinsa combination for first-line mantle cell lymphoma November 06, 2026Vol.52 No.41
Podcast Cercek: “The majority of patients in AZUR-1 in a global study were able to avoid all of standard of care” November 04, 2026
MSK’s Andrea Cercek: Oncology faces learning curve as dostarlimab challenges dMMR rectal cancer standard of care October 30, 2026Vol.52 No.40By Jacquelyn Cobb
Drugs & Targets FDA expands approval of Talzenna + Xtandi for an earlier metastatic prostate cancer treatment setting October 30, 2026Vol.52 No.40
Drugs & Targets FDA releases guidance for sponsors developing gene therapies for rare diseases October 30, 2026Vol.52 No.40By Sara Willa Ernst
In Brief Jessica Zeller named director of the Office of Compliance and Enforcement, FDA Center for Tobacco Products October 23, 2026Vol.52 No.39
Drugs & Targets FDA approves pembro or pembro + berahyaluronidase alfa-pmph for unresectable or metastatic TMB-H solid tumors with updated indication October 23, 2026Vol.52 No.39
Drugs & Targets FDA approves bepirovirsen, first-of-its-kind chronic hepatitis B treatment October 23, 2026Vol.52 No.39
